title: Strategy for the treatment of hairy cell leukemia.
abstract: Both splenectomy and alpha-interferon are efficient treatments for hairy cell leukemia. Since interferon therapy seems to induce remissions of the disease, avoids the risks of surgery, and sustains the spleen, it should be discussed if this therapy may replace splenectomy as primary treatment for this disease. In order to make this decision the biologic relevance of complete remissions in hairy cell leukemia, the reliability of methods to confirm remission, the benefits and risks of both splenectomy and interferon therapy, and some aspects of the pathogenesis of the disease have to be considered. Based on our experimental and clinical results and data from other groups, we conclude that splenectomy should still be recommended as primary therapy in hairy cell leukemia provided that treatment is indicated and the patient is eligible for surgery.
authors: Department of Medicine III, University of Ulm, F.R.G.
authors: F
authors: F
authors: Porzsolt
authors: A
authors: A
authors: Raghavachar
authors: W
authors: W
authors: Digel
authors: A
authors: A
authors: Raghavachar
authors: C R
authors: CR
authors: Bartram
authors: H
authors: H
authors: Heimpel
mesh_terms: D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology; D007943:Leukemia, Hairy Cell / Q000628:therapy*; D007958:Leukocyte Count; D010976:Platelet Count; D013156:Splenectomy; D014777:Virus Diseases / Q000276:immunology
chemical_list: D007370:Interferon Type I